Age and diagnostic performance of Alzheimer disease CSF biomarkers

OBJECTIVES: Core CSF changes in Alzheimer disease (AD) are decreased amyloid β(1–42), increased total tau, and increased phospho-tau, probably indicating amyloid plaque accumulation, axonal degeneration, and tangle pathology, respectively. These biomarkers identify AD already at the predementia stag...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Mattsson, N., Rosén, E., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., Herukka, S.-K., van der Flier, W.M., Blankenstein, M.A., Ewers, M., Rich, K., Kaiser, E., Verbeek, M.M., Olde Rikkert, M., Tsolaki, M., Mulugeta, E., Aarsland, D., Visser, P.J., Schröder, J., Marcusson, J., de Leon, M., Hampel, H., Scheltens, P., Wallin, A., Eriksdotter-Jönhagen, M., Minthon, L., Winblad, B., Blennow, K., Zetterberg, H.
Format: Artigo
Langue:Inglês
Publié: Lippincott Williams & Wilkins 2012
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3280049/
https://ncbi.nlm.nih.gov/pubmed/22302554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3182477eed
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires